J&J Consumer Sales Slip Even As Recalled Brands, Seasonal Items Reach Stores
This article was originally published in The Rose Sheet
Executive Summary
J&J reports worldwide consumer sales dipped 0.6% to $3.6 billion despite retailers buying more upper respiratory and analgesic products to prepare for the cough and cold season. But in key OTC categories the firm is regaining market share it lost when its iconic brands were temporarily not available.
You may also be interested in...
Johnson’s Social-Media Campaign Underscores “Safety Promise” Post-Reformulation
Currently comprising 16 informative YouTube videos, and with 25 more coming before year-end, Johnson’s Baby’s biggest social-media campaign to date has generated 2.3 million views online and sparked a dialogue among millennial moms about Johnson’s products and baby-care issues, the company says. The initiative follows a reformulation initiative announced by J&J in 2011 that removed formaldehyde-releasing preservatives and other controversial ingredients from the line in accordance with consumer demand.
J&J Prioritizes OTC Return With McNeil Remediation End In Sight
Johnson & Johnson CEO Alex Gorsky says bringing recalled OTCs such as Tylenol and Motrin products back to market is the firm’s “clear number one priority” in the near term. J&J also has a timetable for completing its responsibilities under a consent decree with FDA in place since 2011.
Ensuring Leading Position For GSK Consumer Products Touted In Management Shift
GlaxoSmithKline restructures its management to ensure adequate focus on its three core areas, pharmaceutical, vaccine and consumer. Consumer product sales fell 3% to $1.72 billion in the third quarter due to continuing supply interruptions and generally weaker markets.